The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 14, 2025

Filed:

Dec. 31, 2017
Applicant:

United Biomedical, Inc., Hauppauge, NY (US);

Inventors:

Chang Yi Wang, Cold Spring Harbor, NY (US);

Feng Lin, Hauppauge, NY (US);

Jiun Bo Chen, Hauppauge, TW;

Assignee:

United Biomedical, Inc., Hauppauge, NY (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/35 (2006.01); A61K 47/42 (2017.01); C07K 16/42 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/35 (2013.01); A61K 47/42 (2013.01); C07K 16/4291 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55561 (2013.01);
Abstract

The present disclosure is directed to peptide immunogen constructs targeting the extracellular membrane-proximal domain of membrane-bound IgE (or IgE EMPD) and formulations thereof for the treatment of IgE-mediated allergic diseases. The IgE EMPD peptide immunogen constructs have a B cell epitope peptide of more than 20 amino acids, preferably cyclic, linked through an optional spacer to heterologous T helper cell (Th) epitopes derived from pathogen proteins. These peptide immunogen constructs and formulations thereof can stimulate the generation of highly specific antibodies in vaccinated hosts that are directed against the IgE EMPD peptide and are crossreactive with membrane-bound IgE on B lymphocytes committed to IgE secretion. The antibodies induced by the peptide immunogen constructs and formulations thereof in vaccinated hosts can induce apoptosis of IgE-expressing B cells and mediate Antibody Dependent Cellular Cytototoxity (ADCC), resulting in reduction of antigen-specific IgE and total IgE levels in vaccinated hosts to effectively treat IgE-mediated allergic pathology.


Find Patent Forward Citations

Loading…